关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 苏州纳微科技股份有限公司 重要内容提示： | 回购方案首次披露日 | 2024/1/31，由公司实际控制人、董事长江必旺博 士提议 | | --- | --- | | 回购方案实施期限 | 自董事会审议通过后 12 个月内 | | 预计回购金额 | 万元~10,000 万元 5,000 | | 回购用途 | 用于员工持股计划或股权激励 | | 累计已回购股数 | 306.6622 万股 | | 累计已回购股数占总股本比例 | 0.76% | | 累计已回购金额 | 6,099.45 万元 | | 实际回购价格区间 | 元/股~22.18 元/股 15.52 | 一、 回购股份的基本情况 2024年1月29日，公司召开第二届董事会第三十一次会议，审议通过《关于以 集中竞价交易方式回购公司股份的议案》，同意公司以集中竞价交易方式回购公 司股份，回购资金总额不低于人民币5,000万元（含），不超过人民币10,000万元 （含）；回购价格不超 ...

Commercialization Projects - Commercialization projects accounted for 58% of the semi-annual filler revenue [2] - The proportion of commercialization projects is still relatively low, but it is expected to increase as more projects transition to commercial production [2] - The trend of domestic substitution is strengthening, and the proportion of domestic fillers will continue to rise [2] Filler Replacement Cycle - The replacement cycle for fillers in large-scale commercial production varies depending on customer production conditions, frequency, and the specific performance of the filler [2] - Different steps in the production process may require different replacement cycles for fillers [2] - The company focuses on product iteration and innovation while providing technical services for existing projects [2] Market and Product Development - The company, as a leading player in the biopharmaceutical chromatography industry, has a comprehensive product line and extensive application case experience [2] - With the increasing number of commercialization projects, the company is expected to expand its applications further [2]

证券代码：688690 证券简称：纳微科技 公告编号：2024-078 苏州纳微科技股份有限公司 关于召开2024年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议问题征集：投资者可于 2024 年 12 月 5 日 14:00 前访问网址 https://eseb.cn/1jLUzXK9J1m 或使用微信扫描下方小程序码进行会前提问，公司 将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回 答。 一、 说明会类型 苏州纳微科技股份有限公司（以下简称"公司"）已于 2024 年 10 月 30 日发布 公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司经营业绩、 发展战略等情况，公司定于 2024 年 12 月 5 日 14:00-15:00 在"价值在线" （www.ir-online.cn）召开 2024 年第三季度业绩说明会，与投资者进行沟通和交 流，广泛听取投资者的意见和建议。 二、 说明会召开的时间、地点 会议召开时间：2024 ...

证券代码：688690 证券简称：纳微科技 编号：2024-012 | --- | --- | |------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：688690 证券简称：纳微科技 编号：2024-011 | --- | --- | --- | |------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：688690 证券简称：纳微科技 苏州纳微科技股份有限公司 投资者关系活动记录表 编号：2024-010 | --- | --- | |------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：688690 证券简称：纳微科技 苏州纳微科技股份有限公司 投资者关系活动记录表 编号：2024-009 | --- | --- | |------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：688690 证券简称：纳微科技 公告编号：2024-077 苏州纳微科技股份有限公司 二、 回购股份的进展情况 根据《上海证券交易所上市公司自律监管指引第7号——回购股份》等相关规 定，公司在回购股份期间，应当在每个月的前3个交易日内公告截至上月末的回购 进展情况，现将公司回购股份进展情况公告如下： 截止2024年10月31日，公司通过上海证券交易所系统以集中竞价交易方式累 计回购公司股份3,048,822股，占公司总股本403,814,765股的比例为0.76%，回购 成交的最高价为22.18元/股、最低价为15.52元/股，支付的资金总额为人民币 60,642,811.16元（不含印花税、交易佣金等交易费用）。 本次回购股份符合法律法规的规定及公司回购股份方案。 三、 其他事项 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/1/31，由公司实际控制人、董事长江必旺博 士提议 | | --- | --- | | ...

Financial Performance - The company's operating revenue for Q3 2024 was RMB 20,998.02 million, an increase of 34.61% year-on-year[2] - The net profit attributable to shareholders for Q3 2024 was a loss of RMB 304.78 million, a decline of 142.59% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 965.17 million, a decrease of 644.37% year-on-year[2] - The basic earnings per share for Q3 2024 was -0.0076 RMB, down 142.94% from the previous year[2] - In the first three quarters of 2024, the company achieved operating revenue of RMB 550 million, a year-on-year increase of 21.85%[13] - Net profit attributable to shareholders for the first three quarters was RMB 42.0043 million, a year-on-year increase of 7.75%[13] - The net profit for Q3 2024 was CNY 41,282,330.84, an increase from CNY 28,046,231.10 in Q3 2023, representing a growth of approximately 47.4%[19] - The total comprehensive income for Q3 2024 was CNY 40,776,821.93, compared to CNY 28,748,939.23 in Q3 2023, indicating a year-over-year increase of about 42%[20] Research and Development - The company reported a total R&D investment of RMB 5,161.56 million in Q3 2024, accounting for 24.58% of operating revenue, a decrease of 4.62 percentage points year-on-year[3] - Research and development expenses for Q3 2024 amounted to ¥128,692,421.83, slightly down from ¥128,906,037.89 in Q3 2023[18] Assets and Liabilities - The total assets at the end of the reporting period were RMB 225,773.34 million, an increase of 6.17% compared to the end of the previous year[3] - Non-current assets totaled ¥1,087,968,237.70 as of Q3 2024, an increase from ¥948,091,690.29 in Q3 2023[16] - Total assets reached ¥2,257,733,372.74 in Q3 2024, compared to ¥2,126,568,288.37 in Q3 2023, marking an increase of 6.2%[16] - Total liabilities amounted to ¥405,592,619.31 in Q3 2024, a slight increase from ¥396,404,010.92 in Q3 2023[16] Cash Flow and Investments - Cash and cash equivalents decreased to RMB 254.14 million from RMB 339.76 million at the end of 2023[14] - Cash flow from operating activities for the first nine months of 2024 was CNY 30,123,285.58, slightly down from CNY 30,486,954.85 in the same period of 2023[22] - Cash inflow from investment activities in the first nine months of 2024 was CNY 501,561,954.91, significantly higher than CNY 277,523,786.03 in the previous year[22] - The net cash flow from financing activities for the first nine months of 2024 was -CNY 156,748,958.15, compared to -CNY 5,784,948.29 in the same period of 2023, indicating a substantial increase in cash outflow[22] Acquisitions and Impairments - The company completed the acquisition of a portion of Zhejiang Fuli Analytical Instrument Co., which contributed RMB 45.77 million to the consolidated revenue in Q3 2024[8] - The company recognized a goodwill impairment provision of RMB 23 million for the quarter, significantly impacting net profit[8] - The company recognized goodwill impairment of RMB 23.39 million for the acquisition of Saipu Instruments due to market adjustments in the biopharmaceutical and in vitro diagnostics sectors[13] Revenue and Costs - Total operating revenue for Q3 2024 reached ¥549,753,972.67, an increase of 22% compared to ¥451,155,239.81 in Q3 2023[18] - Total operating costs for Q3 2024 were ¥483,916,410.38, up from ¥422,357,702.51 in Q3 2023, reflecting a 14.6% increase[18] - Operating profit for Q3 2024 was ¥46,121,451.81, compared to ¥33,839,440.19 in Q3 2023, representing a growth of 36.1%[18] - Sales revenue from chromatography fillers and chromatography media decreased by 1.74% year-on-year to RMB 316 million, primarily due to increased economic uncertainty and tightened financing in the biopharmaceutical industry[13] Equity and Shareholder Information - The company's equity attributable to shareholders was ¥1,713,412,547.32 in Q3 2024, up from ¥1,703,527,946.74 in Q3 2023[16] - Basic and diluted earnings per share for Q3 2024 were both CNY 0.1045, up from CNY 0.0966 in Q3 2023, reflecting an increase of approximately 9.9%[20]

独立财务顾问报告 2024 年 10 月 证券简称：纳微科技 证券代码：688690 上海荣正企业咨询服务（集团） 股份有限公司 关于 苏州纳微科技股份有限公司 2024 年限制性股票激励计划 预留授予相关事项 之 | 一、释义 | 3 | | --- | --- | | 二、声明 | 4 | | 三、基本假设 | 5 | | 四、独立财务顾问意见 | 6 | | 五、备查文件及咨询方式 | 11 | 一、释义 1. 上市公司、公司、纳微科技：指苏州纳微科技股份有限公司。 2. 股权激励计划、限制性股票激励计划、本激励计划：指《苏州纳微科技 股份有限公司 2024 年限制性股票激励计划（草案）》。 3. 限制性股票、第二类限制性股票：符合激励计划授予条件的激励对象在 满足相应的获益条件后分次获得并登记的公司 A 股普通股股票。 4. 股本总额：指公司股东大会审议通过本计划时公司已发行的股本总额。 5. 激励对象：按照本激励计划规定，获得限制性股票的公司（含全资、控 股子公司，下同）任职的董事、高级管理人员、核心技术人员及骨干员工。 6. 授予日：指公司向激励对象授予限制性股票的日期，授予日必须为交易 日。 7 ...